Markers of inflammation, thrombosis and endothelial activation correlate with carotid IMT regression in stable coronary disease after atorvastatin treatment.

[1]  O. Erdoğan,et al.  Early effects of low versus high dose atorvastatin treatment on coagulation and inflammation parameters in patients with acute coronary syndromes. , 2008, International journal of cardiology.

[2]  D. Baldassarre,et al.  E-selectin and TFPI are associated with carotid intima-media thickness in stable IHD patients: the baseline findings of the MIAMI study. , 2008, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[3]  S. Kinlay.  Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. , 2007, Journal of the American College of Cardiology.

[4]  S. Lee,et al.  Comparison of intensive and low-dose atorvastatin therapy in the reduction of carotid intimal–medial thickness in patients with coronary heart disease , 2007, Heart.

[5]  O. Pachinger,et al.  Effect of atorvastatin on peripheral endothelial function and systemic inflammatory markers in patients with stable coronary artery disease , 2007, Wiener Medizinische Wochenschrift.

[6]  A. Langer,et al.  Increased Soluble Fas Plasma Levels in Subjects at High Cardiovascular Risk: Atorvastatin on Inflammatory Markers (AIM) Study, a Substudy of ACTFAST , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[7]  Y. Aizawa,et al.  The anti-atherosclerotic effects of lipid lowering with atorvastatin in patients with hypercholesterolemia. , 2006, Journal of atherosclerosis and thrombosis.

[8]  A. Blann.  Plasma von Willebrand factor, thrombosis, and the endothelium: The first 30 years , 2005, Thrombosis and Haemostasis.

[9]  Anand N. Shukla,et al.  Prevention of atherosclerosis progression using atorvastatin in normolipidemic coronary artery disease patients--a controlled randomized trial. , 2005, Indian heart journal.

[10]  Y. Dohi,et al.  Effects of atorvastatin on inflammation and oxidative stress , 2005, Heart and Vessels.

[11]  Paul Schoenhagen,et al.  Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. , 2005, The New England journal of medicine.

[12]  E. Tuzcu,et al.  Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease , 2005 .

[13]  M. Pfeffer,et al.  C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.

[14]  J. Ramires,et al.  Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. , 2004, Atherosclerosis.

[15]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[16]  M. Šebeštjen,et al.  Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors , 2004, Thrombosis and Haemostasis.

[17]  P. Libby,et al.  Effect of Atorvastatin on Risk of Recurrent Cardiovascular Events After an Acute Coronary Syndrome Associated With High Soluble CD40 Ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study , 2004, Circulation.

[18]  P. Libby,et al.  Inflammation, Immunity, and HMG-CoA Reductase Inhibitors: Statins as Antiinflammatory Agents? , 2004, Circulation.

[19]  Paul Schoenhagen,et al.  Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. , 2004, JAMA.

[20]  S. Blankenberg,et al.  Adhesion molecules and atherosclerosis. , 2003, Atherosclerosis.

[21]  P. Libby,et al.  High-Dose Atorvastatin Enhances the Decline in Inflammatory Markers in Patients With Acute Coronary Syndromes in the MIRACL Study , 2003, Circulation.

[22]  R. Casamitjana,et al.  Effects of atorvastatin on glucose homeostasis, postprandial triglyceride response and C‐reactive protein in subjects with impaired fasting glucose , 2003, Diabetic medicine : a journal of the British Diabetic Association.

[23]  P. Sager,et al.  Effect of Ezetimibe Coadministered With Atorvastatin in 628 Patients With Primary Hypercholesterolemia: A Prospective, Randomized, Double-Blind Trial , 2003, Circulation.

[24]  Allen J. Taylor,et al.  Effect of atorvastatin and pravastatin on serum C-reactive protein. , 2003, American heart journal.

[25]  M. Trip,et al.  Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. , 2002, Atherosclerosis.

[26]  Allen J. Taylor,et al.  ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: A Randomized Trial Comparing the Effects of Atorvastatin and Pravastatin on Carotid Intima Medial Thickness , 2002, Circulation.

[27]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[28]  E. Arbustini,et al.  Atorvastatin and Thrombogenicity of the Carotid Atherosclerotic Plaque: the ATROCAP Study , 2002, Thrombosis and Haemostasis.

[29]  P Hugh R Barrett,et al.  Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity. , 2002, Clinical chemistry.

[30]  P. Ridker,et al.  Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. , 2002, The American journal of cardiology.

[31]  G. Noseda,et al.  Short-term effects of atorvastatin on C-reactive protein. , 2002, European heart journal.

[32]  A. Seifalian,et al.  The early effect of lipid-lowering treatment on carotid and femoral intima media thickness (IMT). , 2002, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[33]  Z. Galis,et al.  This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: the Good, the Ba , 2022 .

[34]  M. Ezekowitz,et al.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. , 2001, JAMA.

[35]  S. Grundy,et al.  Effect of Hydroxymethyl Glutaryl Coenzyme A Reductase Inhibitor Therapy on High Sensitive C-Reactive Protein Levels , 2001, Circulation.

[36]  M. Trip,et al.  Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial , 2001, The Lancet.

[37]  Jiang He,et al.  Effect of Statins on Risk of Coronary Disease: A Meta-analysis of Randomized Controlled Trials , 2000 .

[38]  J. Larosa,et al.  Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. , 1999, JAMA.

[39]  F. Luscinskas,et al.  MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions , 1999, Nature.

[40]  I. Kushner,et al.  Acute-phase proteins and other systemic responses to inflammation. , 1999, The New England journal of medicine.

[41]  D. Papanicolaou,et al.  The Pathophysiologic Roles of Interleukin-6 in Human Disease , 1998, Annals of Internal Medicine.

[42]  S. Cohen,et al.  Cytokine function: a study in biologic diversity. , 1996, American journal of clinical pathology.

[43]  J. Hansen,et al.  Effect of cholesterol lowering on intravascular pools of TFPI and its anticoagulant potential in type II hyperlipoproteinemia. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[44]  J. Hansen,et al.  Tissue-factor pathway inhibitor and lipoproteins. Evidence for association with and regulation by LDL in human plasma. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[45]  Donald A. Smith.  Fibrinogen as a cardiovascular risk factor: a meta-analysis , 1993, ACP Journal Club.

[46]  A. Lindahl,et al.  Tissue factor pathway inhibitor with high anticoagulant activity is increased in post‐heparin plasma and in plasma from cancer patients , 1991, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[47]  T. Yanagawa,et al.  Atorvastatin lowers plasma low-density lipoprotein cholesterol and C-reactive protein in Japanese type 2 diabetic patients. , 2006, Metabolism: clinical and experimental.

[48]  Thomas Weber,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[49]  A. Meinders,et al.  Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. , 2003, Atherosclerosis.

[50]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[51]  S. Nakao,et al.  Elevated plasma levels of free-form of TFPI antigen in hypercholesterolemic patients. , 2001, Atherosclerosis.

[52]  J. Hansen,et al.  Effect of omega-3 fatty acids and simvastatin on hemostatic risk factors and postprandial hyperlipemia in patients with combined hyperlipemia. , 2000, Arteriosclerosis, thrombosis, and vascular biology.